Q3 2017 EPS Estimates for MacroGenics, Inc. (MGNX) Cut by Analyst

MacroGenics, Inc. (NASDAQ:MGNX) – Equities research analysts at Wedbush lowered their Q3 2017 earnings per share (EPS) estimates for shares of MacroGenics in a research note issued to investors on Thursday. Wedbush analyst D. Nierengarten now expects that the biopharmaceutical company will earn ($0.86) per share for the quarter, down from their previous forecast of ($0.85). Wedbush also issued estimates for MacroGenics’ FY2017 earnings at ($3.96) EPS, Q1 2018 earnings at ($0.97) EPS, Q2 2018 earnings at ($0.88) EPS, Q3 2018 earnings at ($0.91) EPS, Q4 2018 earnings at ($0.93) EPS, FY2018 earnings at ($3.68) EPS, FY2019 earnings at ($4.27) EPS, FY2020 earnings at ($3.24) EPS and FY2021 earnings at $3.28 EPS.

A number of other equities research analysts have also commented on the stock. Morgan Stanley dropped their price objective on shares of MacroGenics from $22.00 to $21.00 and set an “equal weight” rating on the stock in a report on Monday. Cowen and Company restated a “buy” rating on shares of MacroGenics in a report on Friday, August 4th. Zacks Investment Research lowered shares of MacroGenics from a “buy” rating to a “hold” rating in a report on Thursday, August 3rd. ValuEngine lowered shares of MacroGenics from a “sell” rating to a “strong sell” rating in a report on Thursday, August 3rd. Finally, BidaskClub lowered shares of MacroGenics from a “hold” rating to a “sell” rating in a report on Monday, July 31st. Three investment analysts have rated the stock with a sell rating, three have issued a hold rating and nine have assigned a buy rating to the stock. The stock presently has a consensus rating of “Hold” and a consensus price target of $32.30.

TRADEMARK VIOLATION WARNING: This piece was first reported by BNB Daily and is owned by of BNB Daily. If you are reading this piece on another site, it was illegally copied and reposted in violation of international copyright & trademark legislation. The correct version of this piece can be viewed at https://www.baseball-news-blog.com/2017/08/19/q3-2017-eps-estimates-for-macrogenics-inc-mgnx-cut-by-analyst-updated.html.

MacroGenics (NASDAQ MGNX) opened at 16.75 on Monday. The stock’s market capitalization is $616.37 million. The stock’s 50 day moving average is $17.63 and its 200 day moving average is $18.82. MacroGenics has a 12-month low of $14.36 and a 12-month high of $33.30.

MacroGenics (NASDAQ:MGNX) last posted its quarterly earnings results on Wednesday, August 2nd. The biopharmaceutical company reported ($1.14) EPS for the quarter, missing the consensus estimate of ($1.05) by $0.09. MacroGenics had a negative net margin of 1,216.51% and a negative return on equity of 56.81%. The company had revenue of $1.70 million for the quarter, compared to analysts’ expectations of $15.82 million. During the same quarter in the prior year, the firm earned $1.12 earnings per share. The company’s revenue was down 97.9% on a year-over-year basis.

In related news, SVP Jon Marc Wigginton sold 5,000 shares of the firm’s stock in a transaction on Monday, June 5th. The shares were sold at an average price of $20.00, for a total value of $100,000.00. Following the completion of the transaction, the senior vice president now owns 35,000 shares of the company’s stock, valued at $700,000. The transaction was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. 8.30% of the stock is currently owned by company insiders.

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in MGNX. BB Biotech AG increased its position in MacroGenics by 17.7% in the first quarter. BB Biotech AG now owns 2,260,000 shares of the biopharmaceutical company’s stock worth $42,036,000 after buying an additional 340,000 shares during the period. OppenheimerFunds Inc. increased its position in MacroGenics by 9.4% in the first quarter. OppenheimerFunds Inc. now owns 3,323,025 shares of the biopharmaceutical company’s stock worth $61,808,000 after buying an additional 286,018 shares during the period. MARSHALL WACE ASIA Ltd acquired a new position in MacroGenics during the first quarter worth $4,514,000. Marshall Wace North America L.P. acquired a new position in MacroGenics during the first quarter worth $4,514,000. Finally, Bellevue Group AG increased its position in MacroGenics by 267.0% in the first quarter. Bellevue Group AG now owns 304,597 shares of the biopharmaceutical company’s stock worth $5,666,000 after buying an additional 221,597 shares during the period. 82.34% of the stock is owned by institutional investors and hedge funds.

About MacroGenics

MacroGenics, Inc is a clinical-stage biopharmaceutical company focused on discovering and developing monoclonal antibody-based therapeutics for the treatment of cancer, as well as various autoimmune disorders and infectious diseases. The Company develops therapeutic product candidates using its antibody-based technology platforms and also in collaboration with other biopharmaceutical companies.

Earnings History and Estimates for MacroGenics (NASDAQ:MGNX)

Receive News & Ratings for MacroGenics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MacroGenics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply